Risk factors for secondary glaucoma in children


Risk factors for secondary glaucoma in children

For children with uveitis, juvenile idiopathic arthritis-associated uveitis and ANA-positive uveitis without evidence of arthritis are the most common risk factors for developing secondary glaucoma, according to the results of a study published in the May 2006 issue of Ophthalmology.

Karen M. Sijssens MD, and her colleagues from the FC Donders Institute of Ophthalmology, Utrecht, and the University Eye Clinic, Maastricht, The Netherlands, conducted a retrospective, observational case series of 256 eyes of 147 children diagnosed with uveitis before the age of 16.

The researchers were looking for localization and course of uveitis, underlying systemic disease, onset of ocular hypertension, onset of secondary glaucoma, treatment with steroids, antinuclear antibodies (ANAs), lens extractions, number of blind eyes at onset and during follow-up.

Elevated intraocular pressure (IOP) was recorded in 35% of subjects regardless of the form or type of uveitis. However, secondary glaucoma developed more frequently (38%) in juvenile idiopathic arthritis-associated uveitis compared with other forms of uveitis (11%). Secondary glaucoma was also observed more frequently in subjects who were ANA positive (42%) than those who were ANA negative (6%). Except for patients with juvenile idiopathic arthritis-associated uveitis, periocular steroid injections represented an additional risk factor for secondary glaucoma, limited to the early phases of the disease process.

The results suggest a strong link between juvenile idiopathic arthritis-associated uveitis, ANA-positive uveitis and secondary glaucoma.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.